1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > United States Infectious Diagnostics Market Outlook to 2021

United States Infectious Diagnostics Market Outlook to 2021

Summary

GlobalData’s new report, "United States Infectious Diagnostics Market Outlook to 2021", provides key market data on the United States Infectious Diagnostics market. The report provides value, in millions of US dollars within market segments - Hepatitis Viruses, Retroviruses, Infectious Diagnostics Multiple Parameters Panels, Bacteriology, Nucleic Acid Testing Instruments, Other Virology, Infectious Diagnostics Rapid Tests & POC and Parasitology & Mycology.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Infectious Diagnostics market includes Hepatitis Viruses, Retroviruses, Infectious Diagnostics Multiple Parameters Panels, Bacteriology, Nucleic Acid Testing Instruments, Other Virology, Infectious Diagnostics Rapid Tests & POC and Parasitology & Mycology.
- Annualized market revenues (USD million) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
- 2014 company shares and distribution shares data for Infectious Diagnostics market.
- Global corporate-level profiles of key companies operating within the United States Infectious Diagnostics market.
- Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Hologic, Inc., Qiagen N.V., Becton, Dickinson and Company, Danaher Corporation and Alere Inc..

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Table Of Contents

United States Infectious Diagnostics Market Outlook to 2021
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Infectious Diagnostics Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Infectious Diagnostics Market, United States 8
3.1 Infectious Diagnostics Market, United States, Revenue ($m), 2007-2014 8
3.2 Infectious Diagnostics Market, United States, Revenue ($m), 2014-2021 10
3.2.1 Infectious Diagnostics Rapid Tests and POC Market, United States, Revenue ($m), by Segment, 2007-2014 12
3.2.2 Infectious Diagnostics Rapid Tests and POC Market, United States, Revenue ($m), by Segment, 2014-2021 14
3.3 Infectious Diagnostics Market, United States, Distribution Share by Revenue ($m), 2013-2014 16
3.4 Infectious Diagnostics Market, United States, Company Share by Revenue ($m), 2014 17
4 Overview of Key Companies in United States, Infectious Diagnostics Market 19
4.1 Hologic, Inc. 19
4.1.1 Company Overview 19
4.2 Qiagen N.V. 19
4.2.1 Company Overview 19
4.3 Abbott Laboratories 19
4.3.1 Company Overview 19
4.4 F. Hoffmann-La Roche Ltd. 20
4.4.1 Company Overview 20
4.5 Becton, Dickinson and Company 20
4.5.1 Company Overview 20
4.6 Danaher Corporation 20
4.6.1 Company Overview 20
4.7 Alere Inc. 21
4.7.1 Company Overview 21
4.8 Cepheid 21
4.8.1 Company Overview 21
4.9 Siemens Healthcare 21
4.9.1 Company Overview 21
4.10 DiaSorin S.p.A 22
4.10.1 Company Overview 22
4.11 bioMerieux S.A. 22
4.11.1 Company Overview 22
5 Infectious Diagnostics Market Pipeline Products 23
6 Financial Deals Landscape 34
6.1 Acquisition 34
6.1.1 Quest Diagnostics May Sell itself 34
6.1.2 Vivione Biosciences Announces the Expiration of Agreement to Acquire Trillium Diagnostics for USD15 Million 35
6.1.3 Nanosphere Plans to Sell Itself 36
6.1.4 Orgentec Diagnostika to Acquire Corgenix Medical for USD16 Million 37
6.2 Debt Offerings 39
6.2.1 Quidel Prices Public Offering of 3.25% Senior Notes Due 2020 39
6.3 Equity Offerings 41
6.3.1 Trovagene Raises USD40.3 Million in Public Offering of Shares 41
6.3.2 Aethlon Medical to Raise USD6 Million in Private Placement of Shares 43
6.3.3 Trovagene Completes Public Offering of Shares for USD23 Million 44
6.3.4 Vivione Biosciences to Raise USD8 Million in Private Placement of Shares 46
6.3.5 Aethlon Medical Raises USD3.3 Million in Private Placement of Units 47
6.3.6 Nanosphere Terminates Private Placement of Shares for USD30 Million 48
6.4 Partnerships 49
6.4.1 Vivione Biosciences Enters into Distribution Agreement with Trillium Diagnostics 49
6.4.2 PAML Enters into Co-Development Agreement with Axela 50
6.4.3 Biocartis Enters into Licensing and Development Agreement with Microbiome 51
6.4.4 T2 Biosystems Enters into Co-Development Agreement with Canon U.S. Life Sciences 52
6.4.5 BioMerieux Enters into Co-Development Agreement with Illumina 53
6.4.6 Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 54
6.5 Venture Financing 55
6.5.1 Moleculera Labs Raises USD1.1 Million in Venture Financing 55
6.5.2 Lucigen Raises USD2.2 Million in Venture Financing 56
6.5.3 Daktari Diagnostics Raises USD15.5 Million in Series D Financing 57
6.5.4 AdvanDx Raises USD2.5 Million in Venture Financing 58
6.5.5 Rapid Pathogen Screening Raises USD28 Million in Venture Debt Financing 59
6.5.6 DxNow Raises USD0.2 Million in Venture Financing 60
7 Appendix 61
7.1 Research Methodology 62
7.1.1 Coverage 62
7.1.2 Secondary Research 62
7.1.3 Primary Research 62
7.1.4 Company Share Analysis 63
7.1.5 Distribution Share Analysis 63
7.2 GlobalData Consulting 63
7.3 Contact Us 63
7.4 Disclaimer 64

1.1 List of Tables
Table 1: Infectious Diagnostics Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 9
Table 2: Infectious Diagnostics Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 11
Table 3: Infectious Diagnostics Rapid Tests and POC Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 13
Table 4: Infectious Diagnostics Rapid Tests and POC Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 15
Table 5: Infectious Diagnostics Market, United States, Distribution Share by Revenue ($m), USD Constant, 2013-2014 16
Table 6: Infectious Diagnostics Market, United States, Company Share by Revenue ($m), USD Constant, 2014 18
Table 7: Infectious Diagnostics Market Pipeline Products 23
Table 8: Quest Diagnostics May Sell itself 34
Table 9: Vivione Biosciences Announces the Expiration of Agreement to Acquire Trillium Diagnostics for USD15 Million 35
Table 10: Nanosphere Plans to Sell Itself 36
Table 11: Orgentec Diagnostika to Acquire Corgenix Medical for USD16 Million 37
Table 12: Quidel Prices Public Offering of 3.25% Senior Notes Due 2020 39
Table 13: Trovagene Raises USD40.3 Million in Public Offering of Shares 41
Table 14: Aethlon Medical to Raise USD6 Million in Private Placement of Shares 43
Table 15: Trovagene Completes Public Offering of Shares for USD23 Million 44
Table 16: Vivione Biosciences to Raise USD8 Million in Private Placement of Shares 46
Table 17: Aethlon Medical Raises USD3.3 Million in Private Placement of Units 47
Table 18: Nanosphere Terminates Private Placement of Shares for USD30 Million 48
Table 19: Vivione Biosciences Enters into Distribution Agreement with Trillium Diagnostics 49
Table 20: PAML Enters into Co-Development Agreement with Axela 50
Table 21: Biocartis Enters into Licensing and Development Agreement with Microbiome 51
Table 22: T2 Biosystems Enters into Co-Development Agreement with Canon U.S. Life Sciences 52
Table 23: BioMerieux Enters into Co-Development Agreement with Illumina 53
Table 24: Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 54
Table 25: Moleculera Labs Raises USD1.1 Million in Venture Financing 55
Table 26: Lucigen Raises USD2.2 Million in Venture Financing 56
Table 27: Daktari Diagnostics Raises USD15.5 Million in Series D Financing 57
Table 28: AdvanDx Raises USD2.5 Million in Venture Financing 58
Table 29: Rapid Pathogen Screening Raises USD28 Million in Venture Debt Financing 59
Table 30: DxNow Raises USD0.2 Million in Venture Financing 60

1.2 List of Figures
Figure 1: Infectious Diagnostics Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 8
Figure 2: Infectious Diagnostics Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 10
Figure 3: Infectious Diagnostics Rapid Tests and POC Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 12
Figure 4: Infectious Diagnostics Rapid Tests and POC Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 14
Figure 5: Infectious Diagnostics Market, United States, Company Share (%) 2014 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.